The ability of in vivo and in vitro tetanus toxoid (TT) antigen-specific antibody production after the primary immunization with TT vaccine was examined in 5 healthy adults and 3 long term survivors after HLA-identical allogeneic marrow grafting. Serum IgG anti-TT antibody titers became positive in 5 healthy adults but in only one of 3 patients. In vitro spontaneous IgG anti-TT antibody production was detected in 5 healthy adults but only one of 3 patients. In vitro TT antigen-dependent antibody production was detected in 5 healthy adults but only one of 3 patients and the pattern of the patient was different from one of healthy adults. These data indicate that long term survivors after marrow grafting are still disturbed in the ability of in vivo and in vitro TT antigen-specific antibody production after the primary immunization with TT vaccine. It is suggested that impaired spontaneous TT antigen-specific antibody producing B cells and TT antigen-specific memory B cells participate in the impediment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antibody production
20
healthy adults
20
vivo vitro
12
production primary
12
primary immunization
12
antigen-specific antibody
12
adults patients
12
bone marrow
8
marrow transplantation
8
tetanus toxoid
8

Similar Publications

Eczematous paradoxical reactions are commonly associated with anti-interleukin-17A (anti-IL-17A) antibodies. However, IL-23 p19 inhibitors can also cause similar cutaneous manifestations. We present a case of a 77-year-old Japanese woman with palmoplantar pustulosis (PPP), who developed eczematous lesions on her face, neck, and dorsum of the hands 10 weeks after initiating guselkumab treatment.

View Article and Find Full Text PDF

Background: Extracorporeal membrane oxygenation (ECMO) is increasingly used as a bridge to lung transplantation. Although other mechanical circulatory support devices have been associated with anti-human leukocyte antigen antibody formation, including de novo donor-specific antibodies (dnDSA), it is unknown whether ECMO is a sensitizing exposure.

Methods: This was a single-center retrospective cohort study of lung transplant recipients.

View Article and Find Full Text PDF

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature.

Hematology

December 2025

Clinical Pharmacy Department, King Fahad Medical City, Riyadh, RH, Saudi Arabia.

Multiple Myeloma (MM) is a malignancy characterized by abnormal production of monoclonal immunoglobulins in plasma cells. Bispecific antibodies have emerged as a significant advancement in MM treatment, offering high effectiveness and specificity by targeting different antigens such as BCMA, CD38, and FcRH5. However, the risk of infection poses a major challenge in MM patients, which is thought to be influenced by various factors.

View Article and Find Full Text PDF

Background: Patients with estrogen receptor (ER)-positive breast cancer (BC) can be treated with endocrine therapy targeting ER, however, metastatic recurrence occurs in 25% of the patients who have initially been treated. Secreted proteins from tumors play important roles in cancer metastasis but previous methods for isolating secretory proteins had limitations in identifying novel targets.

Methods: We applied an in situ secretory protein labeling technique using TurboID to analyze secretome from tamoxifen-resistant (TAMR) BC.

View Article and Find Full Text PDF

Purpose: This study aimed to compare systemic immune responses and metastatic effects induced by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in murine tumor models. We assessed cytokine production, growth of treated and untreated metastatic tumors, and synergy with immune checkpoint inhibitors (ICIs).

Materials And Methods: Hep55.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!